Periodic Reporting for period 1 - BrainBase (Knowledge management platform for clinical use of brain data)
Periodo di rendicontazione: 2018-09-01 al 2019-02-28
The connectome is a map of all neural connections in the brain that can provide information about the brain’s (re)wiring in neurological diseases, injuries, or drugs responses. The use of connectomes in clinical practice has enormous potential to improve treatment efficacy, enhance patient stratification, disease characterization, and ultimately diagnosis. However, the means to clinically utilize connectomes are limited. Therefore neurologists still rely on subjective analysis of brain scans. Although the use of big data tools in neuro-diagnostics is growing, no commercial application for clinical practice is available yet.
Biomax developed the first commercial solution to translate big connectome data into clinically relevant information: NeuroXM. In combination with patients’ clinical data this can be valorized to improve neuro-diagnosis. NeuroXM has successfully undergone pilot studies at two major institutes. The proprietary NeuroXM platform includes all features and security levels that are required in the clinic. Biomax is a strong bioinformatic SME with 20 years’ experience, including >25 European grants, 5 successful bioinformatic products, and a pioneering reputation.
The objective of the current project was to assess the feasibility of different potential clinical applications of NeuroXM, which will help Biomax to establish a Go/No-go for further clinical validation for the specific clinical applications
Biomax developed the first commercial solution to translate big connectome data into clinically relevant information: NeuroXM. In combination with patients’ clinical data this can be valorized to improve neuro-diagnosis. NeuroXM has successfully undergone pilot studies at two major institutes. The proprietary NeuroXM platform includes all features and security levels that are required in the clinic. Biomax is a strong bioinformatic SME with 20 years’ experience, including >25 European grants, 5 successful bioinformatic products, and a pioneering reputation.
The objective of the current project was to assess the feasibility of different potential clinical applications of NeuroXM, which will help Biomax to establish a Go/No-go for further clinical validation for the specific clinical applications
This feasibility study has assessed different clinical applications, target markets, and a go-to market strategies.
The feasibility study led to the identification of several feasible clinical applications for NeuroXM as well as accessible target markets, generating a go-to market strategy which will help Biomax to proceed to further clinical validation of NeuroXM.